Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/01913913-20110106-02 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Nephrology : what's new in 2024 (II)].
Rev Med Suisse
January 2025
Service de néphrologie, Département de médecine, Hôpitaux universitaires de Genève, Genève 14.
Certain molecules, such as GLP-1 agonists and endothelin antagonists, possess nephroprotective properties. When treating IgA nephropathy, endothelin antagonists and sibeprenlimab have shown effectiveness in slowing the progression of chronic kidney isease. Additionally, the infusion of amino acids can reduce the incidence of mild acute kidney injury following cardiac surgery.
View Article and Find Full Text PDF[Gastroenterology and hepatology : what's new in 2024].
Rev Med Suisse
January 2025
Unité de gastroentérologie, Service de médecine interne, Hôpital Riviera Chablais, 1847 Rennaz.
The year 2024 was rich in developments in the field of hepatology, gastroenterology, and interventional endoscopy. New molecules have been developed for the treatment of metabolic steatohepatitis, primary biliary cirrhosis, and inflammatory bowel diseases. Technological progress now makes it possible to perform screening measurements for portal hypertension directly under echo-endoscopic guidance and to extend the use of intraluminal stents to surgically modified anatomies.
View Article and Find Full Text PDF[Endocrinology : what's new in 2024].
Rev Med Suisse
January 2025
Unité d'endocrinologie, Service d'endocrinologie, diabétologie et métabolisme,Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.
In this article, we look at a selection of recent developments in various areas of endocrinology. We focus on advances in endocrine pharmacotherapy and endocrine surgery, addressing several areas: a) the thyroid safety of Glucagon-Like Peptide-1 (GLP1) analogues; b) the efficacy of adrenal surgery for mild autonomous cortisol secretion; c) crinecerfont in the management of congenital adrenal hyperplasia in adults and children; d) paltusotin as a novel oral therapy for acromegaly and e) TransCon PTH (palopegteriparatide) as a novel therapy for chronic hypoparathyroidism.
View Article and Find Full Text PDFThe treatment of continuous double-level lumbar degenerated disease with PE-TLIF: A case report.
Medicine (Baltimore)
January 2025
Department of Orthopaedic Surgery, Medical College, Yangzhou University, Yangzhou, China.
Rationale: Percutaneous endoscopic transforaminal lumbar interbody fusion (PE-TLIF) is a minimally invasive surgical approach for the treatment of lumbar degenerative diseases, Due to the high incidence of surgical complications and long operative time, the cases reported in previous literature were focused on single segment lumbar degenerative diseases. In our study, we present 2 patients who had continuous double-level lumbar degenerated disease.
Patient Concerns: A 71-year-old man with severe low back pain and right leg pain for 3 months, a 57-year-old woman with severe low back pain and bilateral leg pain for 6 months.
Pathological diagnosis of central nervous system tumours in adults: what's new?
Pathology
December 2024
Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
In the course of the last decade, the pathological diagnosis of many tumours of the central nervous system (CNS) has transitioned from a purely histological to a combined histological and molecular approach, resulting in a more precise 'histomolecular diagnosis'. Unfortunately, translation of this refinement in CNS tumour diagnostics into more effective treatment strategies is lagging behind. There is hope though that incorporating the assessment of predictive markers in the pathological evaluation of CNS tumours will help to improve this situation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!